These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Challenges in detecting disease modification in Parkinson's disease clinical trials. Athauda D; Foltynie T Parkinsonism Relat Disord; 2016 Nov; 32():1-11. PubMed ID: 27499048 [TBL] [Abstract][Full Text] [Related]
3. Intermediate markers as surrogate endpoints in cancer research. Schatzkin A Hematol Oncol Clin North Am; 2000 Aug; 14(4):887-905. PubMed ID: 10949779 [TBL] [Abstract][Full Text] [Related]
4. Biomarkers in Parkinson's disease: Advances and strategies. Delenclos M; Jones DR; McLean PJ; Uitti RJ Parkinsonism Relat Disord; 2016 Jan; 22 Suppl 1(Suppl 1):S106-10. PubMed ID: 26439946 [TBL] [Abstract][Full Text] [Related]
5. Clinical approaches to the development of a neuroprotective therapy for PD. Olanow CW; Kieburtz K; Katz R Exp Neurol; 2017 Dec; 298(Pt B):246-251. PubMed ID: 28622912 [TBL] [Abstract][Full Text] [Related]
6. Outcome measures for clinical trials in Parkinson's disease: achievements and shortcomings. Marras C; Lang AE Expert Rev Neurother; 2004 Nov; 4(6):985-93. PubMed ID: 15853525 [TBL] [Abstract][Full Text] [Related]
7. Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations. Lang AE; Espay AJ Mov Disord; 2018 May; 33(5):660-677. PubMed ID: 29644751 [TBL] [Abstract][Full Text] [Related]
8. Parkinson's disease: 10 years of progress, 1997-2007. Fahn S Mov Disord; 2010; 25 Suppl 1():S2-14. PubMed ID: 20187239 [TBL] [Abstract][Full Text] [Related]
9. New developments in diagnosis and treatment of Parkinson's disease--from basic science to clinical applications. Storch A; Hofer A; Krüger R; Schulz JB; Winkler J; Gerlach M J Neurol; 2004 Sep; 251 Suppl 6():VI/33-8. PubMed ID: 15675723 [TBL] [Abstract][Full Text] [Related]
12. Can Biomarkers Help the Early Diagnosis of Parkinson's Disease? Le W; Dong J; Li S; Korczyn AD Neurosci Bull; 2017 Oct; 33(5):535-542. PubMed ID: 28866850 [TBL] [Abstract][Full Text] [Related]
13. The use of surrogate endpoints in clinical trials: focus on clinical trials in cardiovascular diseases. Lonn E Pharmacoepidemiol Drug Saf; 2001; 10(6):497-508. PubMed ID: 11828831 [TBL] [Abstract][Full Text] [Related]
14. Electrochemical Aptasensors for Parkinson's Disease Biomarkers Detection. Mikuła E; Katrlík J; Rodrigues LR Curr Med Chem; 2022; 29(37):5795-5814. PubMed ID: 35619313 [TBL] [Abstract][Full Text] [Related]
15. The significance of defining preclinical or prodromal Parkinson's disease. Olanow CW; Obeso JA Mov Disord; 2012 Apr; 27(5):666-9. PubMed ID: 22508285 [TBL] [Abstract][Full Text] [Related]
16. Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials. Espay AJ; Schwarzschild MA; Tanner CM; Fernandez HH; Simon DK; Leverenz JB; Merola A; Chen-Plotkin A; Brundin P; Kauffman MA; Erro R; Kieburtz K; Woo D; Macklin EA; Standaert DG; Lang AE Mov Disord; 2017 Mar; 32(3):319-324. PubMed ID: 28233927 [TBL] [Abstract][Full Text] [Related]
17. Role of novel endpoints and evaluations of response in Parkinson disease. Chahine LM; Simuni T Handb Clin Neurol; 2023; 193():325-345. PubMed ID: 36803820 [TBL] [Abstract][Full Text] [Related]
18. Biomarkers of Parkinson's Disease: An Introduction. Titova N; Qamar MA; Chaudhuri KR Int Rev Neurobiol; 2017; 132():183-196. PubMed ID: 28554407 [TBL] [Abstract][Full Text] [Related]
19. Digital Progression Biomarkers as Novel Endpoints in Clinical Trials: A Multistakeholder Perspective. Stephenson D; Badawy R; Mathur S; Tome M; Rochester L J Parkinsons Dis; 2021; 11(s1):S103-S109. PubMed ID: 33579873 [TBL] [Abstract][Full Text] [Related]
20. Biomarkers for the diagnosis and management of Parkinson's disease. Waragai M; Sekiyama K; Fujita M; Tokuda T; Hashimoto M Expert Opin Med Diagn; 2013 Jan; 7(1):71-83. PubMed ID: 23530844 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]